Analysis of RIN1 gene expression in colorectal cancer

Oncology Reports

Volumn 17, Issue 5, 2007, Pages 1171-1175

  Senda, Katsunori ^a   Goi, Takanori ^a   Hirono, Yasuo ^a   Katayama, Kanji ^a   Yamaguchi, Akio ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

Colorectal cancer; RIN1 gene

Indexed keywords

PROTEIN 14 3 3; RIN1 PROTEIN, HUMAN; SIGNAL PEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; CANCER STAGING; CELL STRAIN HT29; COLORECTAL TUMOR; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PROTEIN BINDING; TUMOR CELL LINE;

14-3-3 PROTEINS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; GENE EXPRESSION; HT29 CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM STAGING; PROTEIN BINDING;

EID: 34548570396     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.17.5.1171     Document Type: Article

References (38)

1. Ullrich A and Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212, 1990.
2. Yamashita M, Kimura M, Kubo M, et al: T cell antigen receptor-mediated activation of the Ras/mitogen-activated protein kinase pathway controls interleukin 4 receptor function and type-2 helper T cell differentiation. Proc Natl Acad Sci USA 96: 1024-1029, 1999. (Pubitemid 29072177)
3. Satoh T, Minami Y, Kono T, et al: Interleukin 2-induced activation of Ras requires two domains of interleukin 2 receptor beta subunit, the essential region for growth stimulation and Lck-binding domain. J Biol Chem 267: 25423-25427, 1992.
4. Hubbard SR, Mohammadi M and Schlessinger J: Autoregulatory mechanisms in protein-tyrosine kinases. J Biol Chem 273: 11987-11990, 1998. (Pubitemid 28240552)
5. Heldin CH: Dimerization of cell surface receptors in signal transduction. Cell 80: 213-223, 1995.
6. Pawson T: Protein modules and signalling networks. Nature 373: 573-580, 1995.
7. Buday L and Downward J: Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor. Cell 73: 611-620, 1993. (Pubitemid 23143358)
8. Hunter T: Oncoprotein networks. Cell 88: 333-346, 1997.
9. Boriack-Sjodin PA, Margarit SM, Bar-Sagi D and Kuriyan J: The structural basis of the activation of Ras by Sos. Nature 394: 337-343, 1998. (Pubitemid 28373822)
10. Buday L, Warne PH and Downward J: Downregulation of the Ras activation pathway by MAP kinase phosphorylation of Sos. Oncogene 11: 1327-1331, 1995.
11. Vojtek AB and Der CJ: Increasing complexity of the Ras signaling pathway. J Biol Chem 273: 19925-19928, 1998. (Pubitemid 28377538)
12. Herrmann C, Horn G, Spaargaren M and Wittinghofer A: Differential interaction of the ras family GTP-binding proteins H-Ras, Rap1A, and R-Ras with the putative effector molecules Raf kinase and Ral-guanine nucleotide exchange factor. J Biol Chem 271: 6794-6800, 1996.
13. Pacold ME, Suire S, Perisic O, et al: Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell 103: 931-943, 2000.
14. Deng T and Karin M: c-Fos transcriptional activity stimulated by H-Ras-activated protein kinase distinct from JNK and ERK. Nature 371: 171-175, 1994. (Pubitemid 24284018)
15. Rodriguez-Viciana P, Warne PH, Dhand R, et al: Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370: 527-532, 1994. (Pubitemid 24264918)
16. Feig LA, Urano T and Cantor S: Evidence for a Ras/Ral signaling cascade. Trends Biochem Sci 21: 438-441, 1996. (Pubitemid 26393733)
17. Kuriyama M, Harada N, Kuroda S, et al: Identification of AF-6 and canoe as putative targets for Ras. J Biol Chem 271: 607-610, 1996. (Pubitemid 26034901)
18. Vavvas D, Li X, Avruch J and Zhang XF: Identification of Nore1 as a potential Ras effector. J Biol Chem 273: 5439-5442, 1998. (Pubitemid 28124004)
19. Han L and Colicelli J: A human protein selected for interference with Ras function interacts directly with Ras and competes with Raf1. Mol Cell Biol 15: 1318-1323, 1995.
20. Wang Y and Colicelli J: RAS interaction with effector target RIN1. Methods Enzymol 332: 139-151, 2001. (Pubitemid 32275378)
21. Colicelli J, Nicolette C, Birchmeier C, Rodgers L, Riggs M and Wigler M: Expression of three mammalian cDNAs that interfere with RAS function in Saccharomyces cerevisiae. Proc Natl Acad Sci USA 88: 2913-2917, 1991. (Pubitemid 21916530)
22. Han L, Wong D, Dhaka A, et al: Protein binding and signaling properties of RIN1 suggest a unique effector function. Proc Natl Acad Sci USA 94: 4954-4959, 1997. (Pubitemid 27214717)
23. Afar DE, Han L, McLaughlin J, et al: Regulation of the oncogenic activity of BCR-ABL by a tightly bound substrate protein RIN1. Immunity 6: 773-782, 1997. (Pubitemid 27305739)
24. Wang Y, Waldron RT, Dhaka A, et al: The RAS effector RIN1 directly competes with RAF and is regulated by 14-3-3 proteins. Mol Cell Biol 22: 916-926, 2002. (Pubitemid 34053068)
25. Fleming ID, Cooper JS, Henson DE, et al: AJCC Cancer Staging Manual. 5th edition. Lippincott-Raven, Philadelphia, 1997.
26. Japanese Society for Cancer of the Colon and Rectum: Japanese Classification of Colorectal Carcinoma. 1st English edition. Kanehara, Tokyo, 1997.
27. Goi T, Yamaguchi A, Nakagawara G, Urano T, Shiku H and Furukawa K: Reduced expression of deleted colorectal carcinoma (DCC) protein in established colon cancers. Br J Cancer 77: 466-471, 1998. (Pubitemid 28044053)
28. Sato T, Yamaguchi A, Goi T, et al: Heparanase expression in human colorectal cancer and its relationship to tumor angiogenesis, hematogenous metastasis, and prognosis. J Surg Oncol 87: 174-181, 2004. (Pubitemid 39167384)
29. Vogelstein B, Fearon ER, Hamilton SR, et al: Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525-532, 1988.
30. Takeuchi T, Hisanaga M, Nagao M, et al: The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer. Clin Cancer Res 10: 5572-5579, 2004. (Pubitemid 39100498)
31. Onogawa S, Kitadai Y, Tanaka S, Kuwai T, Kimura S and Chayama K: Expression of VEGF-C and VEGF-D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma. Cancer Sci 95: 32-39, 2004. (Pubitemid 38208404)
32. Goi T, Koneri K, Katayama K, Hirose K and Yamaguchi A: Evaluation of clinicopathological factors and the correlation between the adhesion molecule CD44 variant 9 expression and pulmonary metastases from colorectal cancers. Int Surg 87: 130-136, 2002.
33. Yamaguchi A, Goi T, Taguchi S, et al: Clinical significance of serum levels of CD44 variant exons 8-10 protein in colorectal cancer. J Gastroenterol 33: 349-353, 1998. (Pubitemid 28263649)
34. Waas ET, Wobbes T, Lomme RM, DeGroot J, Ruers T and Hendriks T: Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis. Br J Surg 90: 1556-1564, 2003. (Pubitemid 37533174)
35. Holten-Andersen MN, Christensen IJ, Nielsen HJ, et al: Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res 8: 156-164, 2002. (Pubitemid 34101472)
36. Takamura M, Ichida T, Matsuda Y, et al: Reduced expression of liver-intestine cadherin is associated with progression and lymph node metastasis of human colorectal carcinoma. Cancer Lett 212: 253-259, 2004. (Pubitemid 38997981)
37. Ueda T, Shimada E and Urakawa T: Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J Gastroenterol 29: 423-429, 1994. (Pubitemid 24262709)
38. Kawamoto K, Onodera H, Kan S, Kondo S and Imamura M: Possible paracrine mechanism of insulin-like growth factor-2 in the development of liver metastases from colorectal carcinoma. Cancer 85: 18-25, 1999. (Pubitemid 29031351)